华恒生物：正在筹划发行境外股份（H股）并在香港联交所上市

Core Viewpoint - The company is planning to issue overseas shares (H-shares) and list on the Hong Kong Stock Exchange to advance its global development strategy and enhance brand influence and core competitiveness [1] Group 1 - The initiative aims to optimize the capital structure and broaden diversified financing channels [1] - The company seeks to comprehensively improve governance levels and overall strength [1] - Details regarding the H-share listing are not yet determined, and it will not lead to changes in the controlling shareholder or actual controller [1]